This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
SITC 2022
Presentations
SGN-BB228 | Preclinical | Abstract #1201
SGN-BB228 is a first-in-class CD228-targeted costimulatory Antibody Anticalin® bispecific delivering potent and conditional 4-1BB costimulation to tumor-specific T cells